These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15221100)

  • 41. Characteristics and external validity of the German Health Risk Institute (HRI) Database.
    Andersohn F; Walker J
    Pharmacoepidemiol Drug Saf; 2016 Jan; 25(1):106-9. PubMed ID: 26530279
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Points of view: the role of quality measurement from the Federal Joint Committee's perspective].
    Klakow-Franck R
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(8-9):456-64. PubMed ID: 25523843
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Use of routine data from statutory health insurances for federal health monitoring purposes].
    Ohlmeier C; Frick J; Prütz F; Lampert T; Ziese T; Mikolajczyk R; Garbe E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Apr; 57(4):464-72. PubMed ID: 24658676
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The value of a health insurance database to conduct pharmacoepidemiological studies in oncology.
    Conte C; Vaysse C; Bosco P; Noize P; Fourrier-Reglat A; Despas F; Lapeyre-Mestre M
    Therapie; 2019 Apr; 74(2):279-288. PubMed ID: 30824175
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Data protection and methodological aspects in compiling a routine database from statutory health insurance data for research purposes].
    Ihle P
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Oct; 51(10):1127-34. PubMed ID: 18985406
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Prescription drug atlas 2008--prescription drug utilization in the German national health insurance. The sick patient as a business machine].
    Aumiller J
    MMW Fortschr Med; 2008 Oct; 150(41):7. PubMed ID: 19013836
    [No Abstract]   [Full Text] [Related]  

  • 47. [Measurement of medical outcome quality using administative data in Germany].
    Heller G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Oct; 51(10):1173-82. PubMed ID: 18985411
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Signal detection in pharmacovigilance: empirical evaluation of data mining tools.
    Chan KA; Hauben M
    Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):597-9. PubMed ID: 16134080
    [No Abstract]   [Full Text] [Related]  

  • 49. Establishment of a pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitations.
    Pigeot I; Ahrens W
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):215-23. PubMed ID: 18200610
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Economic evaluation of drug prescription monitoring systems in the extra-hospital environment.
    Lucioni C; Rossi F
    Ann Ist Super Sanita; 1991; 27(2):225-33. PubMed ID: 1755575
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases.
    Maignen F; Hauben M; Hung E; Van Holle L; Dogne JM
    Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):195-207. PubMed ID: 24243665
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Usage of the claim database of national health insurance programme for analysis of cisapride-erythromycin co-medication in Taiwan.
    Gau CS; Chang IS; Lin Wu FL; Yu HT; Huang YW; Chi CL; Chien SY; Lin KM; Liu MY; Wang HP
    Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):86-95. PubMed ID: 17006967
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Brand name or generic? What are the health professionals prescribed for treating diabetes? A longitudinal analysis of the National Health Insurance reimbursement database.
    Liou WS; Hsieh SC; Chang WY; Wu GH; Huang HS; Lee C
    Pharmacoepidemiol Drug Saf; 2013 Jul; 22(7):752-9. PubMed ID: 23625864
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Decision-analytical modelling of costs per QALY in the context of the German Social Law].
    Rogowski WH; Landauer M; John J
    Gesundheitswesen; 2009 Nov; 71(11):739-50. PubMed ID: 19551622
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Services and benefits for medical rehabilitation and integrated health care].
    Fuchs H
    Rehabilitation (Stuttg); 2004 Oct; 43(5):325-34. PubMed ID: 15472791
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The influence of prescription drug insurance on psychotropic and non-psychotropic drug utilization in Canada.
    Sarma S; Basu K; Gupta A
    Soc Sci Med; 2007 Dec; 65(12):2553-65. PubMed ID: 17761377
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Health insurance discount contracts: problems and risks for the general practitioner in the medical care of patients with chronic illness].
    Leutgeb R; Mahler C; Laux G; Weschnetz A; Szecsenyi J
    Dtsch Med Wochenschr; 2009 Jan; 134(5):181-6. PubMed ID: 19180404
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Linkage of statutory health insurance data with those of a hospital information system: feasible, but also "useful"?].
    Ohlmeier C; Hoffmann F; Giersiepen K; Rothgang H; Mikolajczyk R; Appelrat HJ; Elsässer A; Garbe E
    Gesundheitswesen; 2015 Feb; 77(2):e8-e14. PubMed ID: 25622210
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Fraud in the health-care system from the perspective of the public health insurance companies. Empirical findings on the work of anti-fraud agencies].
    Meier BD; Homann D
    Gesundheitswesen; 2010 Jul; 72(7):404-11. PubMed ID: 19890808
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Medical prescription of cannabis-the legal situation becomes clarified].
    Tolmein O
    Schmerz; 2019 Oct; 33(5):443-448. PubMed ID: 31478141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.